News

Actelion claimed the prestigious title of marketing company of the year at the PharmaTimes Marketer & Communications Team of the Year awards last night.

The US Food and Drug Administration has expanded the scope of Harvoni allowing its use in patients with genotype 4, 5 and 6 chronic hepatitis C virus infection and in those co-infected with HIV.

NHS England and Health Education England have rolled out a new national training programme to help nurture and keep the most inventive and innovative clinicians on UK shores.

The National Institute for Health and Care Excellence has published its first set of guidelines for the treatment of menopause, stressing that women should no longer have to suffer in silence.

There is no evidence to support a causal link between human papillomavirus vaccines and the development of two conditions – complex regional pain syndrome (CRPS) and postural orthostatic tachycardia syndrome (POTS), European regulators have confirmed.

GP leaders say they are seriously concerned about poor uptake of this year’s flu vaccine, which they warn is risking the health of thousands of people.

Despite initiatives to reduce the number of prescriptions for antibiotics in England a rise is being recorded in the country’s most deprived areas.

Boehringer Ingelheim has linked hands with four different academic institutions under an overarching aim to accelerate the development of new therapies for inflammatory bowel disease.

The US Food and Drug Administration has green lighted Roche’s Cotellic for use in combination with Zelboraf to treat some patients with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma.

NHS England has published interim guidance allowing the use of adalimumab (AbbVie’s Humira) to treat children with severe refractory uveitis, an inflammation of the middle layer of the eye.

Pharmaceutical companies are finding it difficult to recruit for high skilled roles in the UK because of a shallow pool of good quality candidates, raising concerns that the country’s standing in global research and development is in danger of being weakened.

AstraZeneca’s lupus drug anifrolumab has achieved its primary and secondary endpoints in Phase II trial, significantly reducing disease activity versus placebo across multiple endpoints.

The US Food and Drug Administration has assigned Teva’s SD-809 Breakthrough Therapy Designation for the treatment of patients with moderate-to-severe tardive dyskinesia, a hyperkinetic movement disorder affecting about 500,000 people in the US.

Scottish cost regulators have approved four new therapies for use on the National Health Service in Scotland, offering patients access to new treatments for skin cancer, ovarian cancer and deep vein thrombosis.

Johnson & Johnson group Janssen has picked up worldwide rights, excluding China and Korea, to develop and commercialise oxyntomodulin-based therapies from Hanmi Pharmaceutical, beefing up its metabolism portfolio.